

CVC Working Group Monthly Meeting Minutes

Thursday, January 13, 2022

11am-12pm PT | 1-2pm CT | 2-3pm ET | 3-4pm AT

No	Description	Notes	Time
1	Welcome		
2	COVID-19 Terminology Discussion	<p>1. Pfizer BioNTech Comirnaty tris-sucrose, 12+</p> <ul style="list-style-type: none"> ● Review of proposed terminology <p>Decisions/Action Items</p> <ul style="list-style-type: none"> ● Pfizer has not yet submitted application for approval to Health Canada. ● CHI will process RFC next week. ● See meeting presentation for proposed terminology. <p>2. Moderna Pediatric Dose Discussion</p> <ul style="list-style-type: none"> ● Discuss any updates <p>Decisions/Action Items</p> <ul style="list-style-type: none"> ● Update from Bolaji (PHAC): Health Canada has asked for more data on a lower dose, which may lead to a modification of strength. ● Follow-up on this for next meeting. 	Group discussion
3	Other RFCs	<p>HyperTET</p> <ul style="list-style-type: none"> ● Review of RFC (request from BC) ● Confirm DIN for Hypertet S/D <p>Decisions/Action Items</p> <ul style="list-style-type: none"> ● RFC will be processed by CHI next week (link to RFC: https://informs.infoway-inforoute.ca/browse/SCT-12550?filter=-2) ● RFC submitted to revise display/preferred term for existing concept 7981000087105 HYPERTET S/D 250 units per dose solution for injection Grifols Canada Limited (product) (link to RFC: https://informs.infoway-inforoute.ca/browse/SCT-12657?filter=-2) <ul style="list-style-type: none"> ○ DIN for this concept should also be changed from 02379619 (cancelled pre market) to 02230697 (marketed) 	Helen Xing (BCCDC)

4	SNOMED-CT Updates and Data Quality	<ul style="list-style-type: none"> ● Analysis & summary of updates ● Proposed timeline for review by stakeholders <p>Decisions/Action Items</p> <ul style="list-style-type: none"> ● Jurisdictions need more time to review before these changes are published in the CVC. ● CVC team to prepare delta file with what is currently in the CVC and what proposed changes are, by concept, and share with stakeholders early next week <ul style="list-style-type: none"> ○ Includes proposing new generic parent ID mapping in for each trade name product where applicable (as many concepts were inactivated) ● Discussion of any questions and implementation timeline to be revisited at next CVC meeting. 	Taylor
5	1.1.16 Release Summary	<p>Go over what will be included in the next CVC release & target release date</p> <p>Decisions/Action Items</p> <ul style="list-style-type: none"> ● Next release will include lot/expiry information for all vaccines (including COVID-19) for months of January, February ● Will also include HyperTET, pending concept creation. ● Target release: early February 	Taylor
6	Wrap up	<p>Next meeting</p> <ul style="list-style-type: none"> ● Thursday, February 15, 2022 from 2-3pm ET <p>Register in advance for this meeting: https://infoway-inforoute.zoom.us/meeting/register/tZYkduCurD0qHtKYuK6SLujC3ZTJdNkJGVPq</p>	Alicia